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Abstract
Background: To study the relationship between the rs12255372 (G/T) polymorphism of the transcription factor
7-like 2 (TCF7L2) and type 2 diabetes mellitus (T2DM) in a Cameroonian population.
Methods: This case–control study included 60 T2DM patients and 60 healthy normoglycemic controls, all unrelated and
of Cameroonian origin, aged above 40 years (range 40–87). The Restriction Fragment Length Polymorphism - Polymerase
Chain Reaction (RFLP-PCR) was used for genotyping.
Results: The T allele frequency was significantly higher in the diabetic group (0.44) than in the control group (0.17). This
allele was significantly associated to a greater risk of developing T2DM as compared to the G allele (OR = 3.92,
95% CI 2.04 – 7.67, p < 0.0001). The codominant (additive) model explained best the risk of developing the
disease, as the TT genotype was significantly associated to T2DM when compared to the GG genotype (OR = 4.45, 95% CI
1.64 – 12.83, p = 0.0014). By logistic regression adjusted for age, this OR was 4.33 (95% CI: 1.57 – 11.92, p = 0.005).
Conclusion: Our findings suggest that the rs12255372 (G/T) polymorphism of the TCF7L2 gene is an important risk factor
for T2DM in the Cameroonian population.
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Background
Diabetes is a non-communicable disease characterized
by chronic hyperglycemia and disturbances in carbohy-
drates, lipids and proteins metabolism due to defects in in-
sulin secretion and its action, which results in severe acute
and chronic complications [1]. Diabetes mellitus is a major
public health problem worldwide. Estimates from the Inter-
national Diabetes Federation (IDF) indicate that there were
about 381.8 million adults with diabetes mellitus in the
world in 2013. This prevalence is projected to expand by
55% in 2035 to reach 591.9 million of adults affected [2].
Type 2 diabetes mellitus (T2DM) causes important mor-
bidity, disability and early mortality, and is associated with a
huge economic burden [3].
T2DM is the most heterogeneous form of diabetes
which is due by interactions between genetic and environ-
mental factors. Genome-wide association studies have led
to the identification of several susceptibility genes for
T2DM [4], including the gene coding for the transcription
factor 7-like 2 (TCF7L2). TCF7L2 is involved in insulin se-
cretion [5,6]. It intervenes in the “wingless” (WNT) signali-
zation in β pancreatic cells, L cells of the intestine and in
adipocytes [7]. An association study reported a relationship
between a common micro-satellite (DG10S478) in intron 3
of the TCF7L2 gene and T2DM [8]. Other studies identified
4 other polymorphisms of the TCF7L2 gene associated to
T2DM, amongst which rs7903146 (C/T), rs7901695 (T/C),
rs12255372 (G/T) and rs11196205 (G/C) [9,10]. Even
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though most studies demonstrated a strong association be-
tween the TCF7L2 rs7903146 (C/T) variants with T2DM,
some few have also shown a strong association with the
rs12255372 (G/T) variants [11-17]. On the contrary, no as-
sociation between the rs12255372 (G/T) variants and
T2DM have been found in Chinese [18], Arabs [19], Pima
Indians [20] and South-Africans [21].
The relationship between the TCF7L2 variants gene
and T2DM has never been studied in Central African
populations where T2DM is very prevalent, with high
morbidity and mortality rates [2]. Hence we decided to
set bases with this pilot study by investigating the associ-
ation between the TCF7L2 rs12255372 (G/T) poly-
morphism and T2DM in a Cameroonian population.
Methods
Study population
This is a case–control study involving 60 T2DM patients
and 60 non-diabetic controls of Cameroonian ethnicity
aged over 40 years. T2DM patients, diagnosed according
to the IDF criteria [22], were consecutively recruited
through the outpatient clinic of the National Obesity
Center of the Yaoundé Central Hospital, Yaoundé,
Cameroon. Pregnant or breastfeeding women were ex-
cluded. Non-diabetic controls were recruited from the
general population and included in the study after
being tested negative for diabetes (fasting plasma glu-
cose <126 mg/dL) [22].
For all participants, we collected data on the sex and
age; height, waist and hip circumference to the nearest
0.5 cm, and weight in light clothes to the nearest 0.1 kg
were measured. The body mass index (BMI) as weight in
kg/height2 in m2, and the waist-to-hip ratio were calcu-
lated. The resting blood pressures were measured using
standardized procedures with an automatic sphygmo-
manometer Omron HEM-705 CP (Omron Corporation,
Tokyo, Japan).
Biochemical assays and molecular genotyping
Blood samples were collected for biochemical and
molecular assays. Fasting plasma glucose (glucose
oxidase–peroxidase method), serum triglycerides (glycerol
phosphatase oxidase-phenol4-amino antipyrene peroxidase
method), serum cholesterol and high-density lipoprotein
(HDL)-cholesterol (cholesterol oxidase phenol4-amino
antipyrene peroxidase method) were determined by
spectrophotometer (UV Mini 1240) using Chronolab
kits (Chronolab Systems, Barcelona, Spain). Low-density
lipoprotein (LDL)-cholesterol was calculated using the
Friedwald’s formula [23].
Genomic DNA was extracted from whole blood on
filter paper by the Chelex method [24] and stored at
−20°C. The rs12255372 (G/T) polymorphism of the
TCF7L2 was genotyped by Restriction Fragment Length
Polymorphism – Polymerase Chain Reaction (RFLP-
PCR) using the following primers: Forward 5′-CTG
GAA ACT AAG GCG TGA GG-3′, Reverse 5′-GGG
TCG ATG TTG TTG AGC TT-3 (SIGMA-ALDRICH,
St. Louis, Missouri, United States). A final reaction vol-
ume of 20 μL for the Polymerase Chain Reaction (PCR)
was constituted, which contained 100 ng of genomic
DNA, 0.25 μM of each primer, 1.5 mM of MgCl2,
0.2 mM of each deoxynucleotide triphosphate (dNTP),
0.5 U of Go Green Taq DNA polymerase (PROMEGA),
1× Go Green Flexi buffer and 11.3 μl of nuclease free water.
The PCR was carried out on a BIOMETRA T3 Thermal
Cycler under the following conditions: 95°C for 2 minutes,
followed by 35 cycles of 95°C for 30 seconds, 54°C for
30 seconds, 72°C for 30 seconds, and a final extension of
72°C for 5 minutes. The amplicons (346 bp) were then
digested with Thermus species (Tsp509I) restriction
enzyme at 65°C for 3 hours. The reaction volume was
set to 15 μl, containing 7 μl of amplicons, 1× NEB
buffer1 (New England Biolabs), 1U of Tsp509I, and
6.3 μl of nuclease free water. The digested products
were separated by electrophoresis on a 3.5% agarose gel
in presence of ethidium bromide (10 mg/mL) and visu-
alized under a UV transilluminator.
Ethical considerations
The study was approved by the National Ethical Review
Board of the Cameroon Ministry of Public Health. Written
informed consent was obtained from all the participants.
The study was conducted in accordance with the Helsinki
Declaration.
Statistical analysis
Data was analyzed with STATA 11.0 (STATA Corporation,
College Station, Texas, USA). Genotype and allele fre-
quencies were compared using the χ2 statistics or the fish-
er’s exact test. Continuous variables were compared using
non parametric tests (Mann Whitney or Kruskall Wallis
with post hoc multiple comparison by Dunn-Sidak test).
The Hardy Weinberg equilibrium was tested using the
goodness-of-fit chi-square. Odd ratios were calculated by
logistic regression adjusting for age. A p value less than
0.05 was considered statistically significant.
Results
Significant differences between T2DM patients and
normoglycemic controls were observed for age (median
age – 60 years vs 50 , p < 0.0001), waist-to-hip ratio
(median value - 0.96 vs 0.87, p < 0.0001), fasting plasma
glucose (median level - 1.49 vs 0.91, p < 0.0001), total
cholesterol (median level - 163.00 vs 191.00, p < 0.0001)
and LDL-cholesterol (median level - 86.00 vs 110.00,
p < 0.0001) (Table 1).
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From the 120 participants, five cases were excluded
from the final analysis because of negative genotypic re-
sults. One hundred and fifteen cases were positive for
genotyping, characterized on agarose gel by two bands
of 143 bp and 104 bp for the wild type homozygote GG,
two bands of 126 bp and 104 bp for the mutant homozy-
gote TT, and three bands of 143 bp, 126 bp and 104 bp
for the mutant heterozygote GT. Fragments smaller than
the 100 bp of the molecular weight marker were not vi-
sualized (Figure 1).
The frequency of the GG genotype was 66.96% (77/115),
versus 5.21% (6/115) and 27.82% (32/115) for the GT and
the TT genotypes respectively. Genotype frequencies vio-
lated the Hardy-Weinberg equilibrium in the general popu-
lation. The G allele was major with a frequency of 70%, as
compared to the minor T allele which showed a frequency
of 30%. The T allele frequency was 43.96% in diabetic group
against 16.7% in nondiabetic and was found to significantly
increase the risk of T2DM with an odds ratio of 3.92 (95%
CI 2.04 – 7.67, p < 0.0001) (Table 2).
The frequency of the TT genotype was significantly
higher in diabetics than in controls (41.37% vs. 14.03%)
and was found to be significantly associated to T2DM
with an OR of 4.45 (95% CI 1.64 – 12.83, p = 0.0014)
(Table 2).
Dominant, recessive and codominant models of inher-
itance were tested to identify which of them best fit the
effect of the TCF7L2 rs12255372 (G/T) polymorphism on
T2DM. Assuming the dominant model (GG vs. GT +TT=
XT), the T allele carriers (XT genotype) had a significantly
higher risk of T2DM than those with the GG genotype with
an OR of 3.64 (95% CI 1.47 – 9.30, p = 0.0028). When
assuming the recessive model (GX =GG+GT vs. TT), a
significant association was also found with an OR of 4.32
(95% CI 1.62 – 12.36, p = 0.00016). Thus, the highest risk
was observed with the codominant model with an OR of
4.45 (95% CI 1.64 – 12.83, p = 0.0014)/4.33 (95% CI: 1.57 –
11.92, p = 0.005), after adjusting for age (Table 2).
Based on rs12255372 (G/T) genotypes, the clinical
(BMI, waist-to-hip ratio, systolic blood pressure and dia-
stolic blood pressure) and biochemical (fasting plasma glu-
cose, total cholesterol, LDL-cholesterol, HDL-cholesterol
and triglycerides) characteristics of the T2DM patients were
stratified, and no association was found. Comparative ana-
lyses of normoglycemic controls and rs12255372 (G/T) ge-
notypes also revealed no association with anthropometrical
and biochemical characteristics (data not shown).
Discussion
Although the burden of T2DM is huge in sub-Saharan
populations, epidemiological data on the disease are lim-
ited, especially on the genetic determinants of the disease
[25]. This pilot study aimed to assess the association be-
tween the rs12255372 (G/T) polymorphism of the TCF7L2
Table 1 Clinical and biological characteristics of the study
population
Variables Normoglycemic
individuals (n = 60)
Type 2 diabetes
patients (n = 60)
P value
Age (years) 50 (45 – 54) 60 (53 – 67) <0.0001
Male/female ratio 20/40 28/32 0.136
Waist-to-hip ratio 0.87 (0.81 – 0.91) 0.96 (0.91 – 0.98) < 0.0001
Systolic blood
pressure (mmHg)
136 (120 – 152) 130 (118 – 152) 0.70
Diastolic blood
pressure (mmHg)
83.5 (76 – 93) 78 (71.25 – 87) 0.034
Body mass index
(kg/m2)
28.39 (26.05 – 32) 27.85 (25.01 – 33.56) 0.59
Fasting plasma
glucose (g/L)
0.91 (0.84 – 1.00) 1.49 (1.27 – 2.08) <0.0001
Total cholesterol
(mg/dl)
191 (173 – 210) 163 (149 – 179) <0.0001
HDL-cholesterol,
mg/dl
50 (46 – 54) 48.5 (44 – 52.75) 0.070
LDL-cholesterol,
mg/dl
110 (91.25 – 138.5) 86 (76.25 – 100) <0.0001
Tryglicerides
(mg/dl)
141.5 (129.5 – 161.8) 136 (122 – 157.5) 0.124
Data are medians (interquartile range) unless otherwise stated.
HDL-cholesterol: high density lipoprotein cholesterol; LDL-cholesterol: low
density lipoprotein cholesterol.
Figure 1 PCR-restriction fragment length polymorphism detection
of the TCF7L2 rs12255372 (G/T) polymorphism. PCR followed by
digestion with TSP509I - 3.5% agarose gel electrophoresis followed
by ethidium bromide staining and UV transilluminator was performed.
The expected product sizes are: normal homozygote GG, 143 bp,
104 bp; mutant homozygote TT, 126 bp, 104 bp; and heterozygote GT,
143, 126, and 104 bp, respectively. MWM: 100 bp Molecular weight
marker; fragments smaller than 100 bp were not visualized.
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gene with T2DM in a Cameroonian population. The fre-
quency of the minor T allele was found to be 30%, and was
comparable to those observed in the Czech population
(30.15%) [26], the Iranian population (34.45%) [13] and the
Arab population (36.15%) [19]. The variation of the T allele
frequency across population could be explained by the
genetic diversity between different ethnic groups [14]. This
allele was found to be significantly associated to the risk of
T2DM with an OR of 3.92 (95% CI 2.04 – 7.67, p < 0.0001).
This result is consistent with those reported by previous
studies in different populations [13,16,17], where a strong
association was noted between this polymorphism and the
risk of T2DM. Furthermore, a weak association was
reported in West-Africa, with an OR of 1.31 (95% CI
1.01–1.69, P = 0.044) [27] and in Afro-Americans [28].
However, no association between a TCF7L2 rs12255372
(G/T) variant and T2D was found in Chinese [18], Arab
[19], Pima Indians [20], and South-African (Zulu
offspring) [21] populations.
The frequency of the TT genotype was significantly
higher in diabetic patients than normoglycemic individ-
uals (41.37% vs. 14.03%, p = 0.0014). The GT genotype
frequency was similar between the 2 groups and no as-
sociation was found with of T2D. When assuming 3
models (dominance, recessivity, and codominance) to
explain the association between the rs12255372 (G/T)
polymorphism of the TCF7L2 gene and T2D, the co-
dominant model best fitted the association with an OR
of 4.45 (95% CI 1.64 – 12.83, p = 0.0014)/OR (adjusted
for age) of 4.33 (95% CI: 1.57 – 11.92, p = 0.005), thus a
4-fold risk increase. This finding is in accord with that
of Faranak et al. who demonstrated that the codominant
model best fitted the effect of these gene variant on the
risk of T2DM in the Iranian population [13]. A meta-
analysis published in 2009 showed that the magnitude of
association between this gene variant and T2DM is
moderate and that the TT homozygous variant will ap-
proximately cause a 2-fold increase in T2DM [10]. Our
value was higher (about 2-times higher), and could have
been due to our sample size which was not adequate
(small) for this kind of study, as we noted very big confi-
dence intervals for odds Ratio. Despite that, differences
in ethnic background, environmental factors such as life-
style also could explain the risk difference. Even though the
biological mechanism for the association between the
TCF7L2 gene and the risk of T2DM is still unclear, it can
be speculated that the TCF7L2 gene has a role in insulin se-
cretion and possibly adipose tissue development. Further-
more, the genetic variants that have so far been studied are
present in the introns rather than in the coding regions.
However, this may still lead to functional consequences in
terms of protein stability and/or expression of alternatively
spliced variants [12].
This study, with a caution on sample size showed an
association between the rs12255372 (G/T) polymorphism
of the TCF7L2 gene and type 2 Diabetes in a Cameroonian
population. The Hardy-Weinberg equilibrium was violated
in the general population, and this could have been due to
genotyping errors, as RFLP-PCR data is sometimes difficult
to interpret. For this reason, we excluded all doubtful geno-
types from analysis. Deviation from Hardy-Weinberg equi-
librium in this study was most probably due to our small
sample size [29].Thus, our findings have to be replicated
with a large sample size and genotyping has to be done
using more sensitive techniques such as the Taqman probe
assay on real time PCR, or by direct sequencing, as RFLP-
PCR data are sometimes difficult to appreciate. Controls
have to be carefully selected in other to avoid confounding
by population stratification. However, despite the relative
small sample size of the study, the high odd ratio and level
of statistical significance found are clear indications that
there is most probably an association between rs12255372
TCF7L2 and T2DM in our population.
Conclusion
The rs12255372 (G/T) polymorphism of the TCF7L2 gene
is probably associated with T2DM in this population. This
variant could help to predict the occurrence of T2DM in
the Cameroonian population and possibly other sub-
Saharan populations. Our findings should be confirmed by
larger study with more accurate genotyping tools.
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Table 2 Association between the TCF7L2 rs12255372 (G/T)







OR (95% CI) p value
Alleles
G 95 (83.33) 65 (56.03) / /
T 19 (16.7) 51 (43.96) 3.92 (2.04 – 7.67) 0.0001
Total (2 N) 114 116
Genotypes
GG 46 (80.7) 31 (53.44) /
GT 3 (5.26) 3 (5.17) 1.48 (0.18 – 11.75) 0.68
TT 8 (14.03) 24 (41.37) 4.45 (1.64 – 12.83)/
4.33* (1.57 – 11.92)
0.0014/0.005*
Total (N) 57 58
T2DM: Type 2 diabetes mellitus; OR: odd ratio; *age-adjusted odd ratio.
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